The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.


Guest:

Caleb Alexander, Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health


View the transcript for today's episode: https://tradeoffs.org/2021/06/03/the-fdas-pressure-packed-alzheimers-drug-decision


Take our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurvey


Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter


Support this type of journalism today, with a gift: https://tradeoffs.org/donate


Follow us on Twitter: https://twitter.com/tradeoffspod


Hosted on Acast. See acast.com/privacy for more information.

More from Tradeoffs

  1. 26:34How Do You Help Patients Who Show Up in the ER 100 Times a Year?Apr 25, 2024
  2. 20:35An Insurance Company Bought This Doctor’s Practice. She’s Worried About Her PatientsApr 18, 2024
  3. 20:4992,000 Transgender People Took This Survey. Here’s What We LearnedApr 11, 2024
  4. 23:32Girls Are in a Mental Health Crisis. What Can Schools Do?Apr 04, 2024
  5. 19:41Surprise! Plans To Resolve High Medical Bills Are Still a MessMar 28, 2024
  6. 31:17One Doctor’s Quest to Improve Health Care for People with DisabilitiesMar 21, 2024
  7. 22:11Can Washington Make Medicare and Medicaid Work Better Together?Mar 14, 2024
  8. 24:29How Patient Privacy Could Hurt AIMar 07, 2024
  9. 18:02How Pushing Hospitals to Give Away More Free Care Could BackfireFeb 29, 2024
  10. 23:28‘She Didn’t Want to Die. But She Didn’t Want to Suffer.’Feb 22, 2024